Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vryalar

- PMLiVE

Allergan CEO takes issue with ‘predatory’ price increases

Saunders adds voice to drug pricing outcry saying perpetrators break “social contract”

Shire Basingstoke

Shire launches dry eye drug Xiidra in US

Sparks rivalry with Allergan’s blockbuster Restasis as first new dry eye treatment in 13 years

Deal Watch July 2016

Real deals, real money and - for some - reality bites

- PMLiVE

Teva acquires Allergan’s generics operations in $38.8bn deal

Also discloses $500m agreement to purchase the Irish firm’s distribution business

Deal Watch June 2016

Allergan, Novartis and Merck & Co are among those featured in this month's round-up of pharma deal activity

- PMLiVE

AZ gets EU green light for new antibiotic Zavicefta

EMA approves combination drug for treatment of multidrug resistant infections

Allergan logo

Allergan on course to file uterine fibroid drug next year

New drug could be safer and more effective than existing treatment

- PMLiVE

Pfizer split still on cards – for tax reasons

Firm continues to look for ways to reduce tax burden

Allergan logo

Allergan eyes early 2017 European launch for Enzepi

CHMP backs the enzyme replacement therapy's approval

- PMLiVE

US tax changes claim Pfizer scalp as Allergan deal abandoned

Firm walks away from record-breaking $160bn merger after planned inversion rule changes released

- PMLiVE

Pfizer and Allergan: The challenge starts now

The Pfizer and Allergan merger is a game changer in the pharmaceutical industry, creating the biggest drug maker in the world. The complexities of reaching this landmark agreement cannot be...

- PMLiVE

Size matters?

Pfizer’s $160bn deal to acquire Allergan will challenge the new company to show that big is better

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links